Pazopanib for the treatment of breast cancer. [Review]
Citation: Expert Opinion on Investigational Drugs. 21(2):217-25, 2012 Feb.PMID: 22233389Institution: Washington Cancer InstituteForm of publication: Journal ArticleMedline article type(s): Journal Article | Research Support, N.I.H., Extramural | ReviewSubject headings: *Angiogenesis Inhibitors/tu [Therapeutic Use] | *Breast Neoplasms/dt [Drug Therapy] | *Protein Kinase Inhibitors/tu [Therapeutic Use] | *Pyrimidines/tu [Therapeutic Use] | *Sulfonamides/tu [Therapeutic Use] | Breast Neoplasms/ge [Genetics] | Female | Humans | Protein-Tyrosine Kinases/ai [Antagonists & Inhibitors] | Tumor Markers, BiologicalYear: 2012ISSN:- 1354-3784
Item type | Current library | Collection | Call number | Status | Date due | Barcode |
---|---|---|---|---|---|---|
Journal Article | MedStar Authors Catalog | Article | 22233389 | Available | 22233389 |
INTRODUCTION: Several clinical trials have shown clinical benefit of angiogenesis inhibitors in the treatment of solid tumors. Pazopanib is a multitargeted tyrosine kinase inhibitor that is currently approved for the treatment of patients with advanced renal cell carcinoma (RCC). AREAS COVERED: In this article, the clinical development of pazopanib as it relates to breast cancer is reviewed including its evaluation in clinical trials and side effect profile. Preclinical data show the anti-tumor activity of pazopanib in animal models. Several trials of pazopanib monotherapy and combination therapy in breast cancer have been completed or are underway. EXPERT OPINION: The development of biomarkers predictive of response and toxicity to angiogenesis inhibitors remains a challenging endeavor and is necessary to help guide treatment decision.
English